一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

ChemicalBook >> journal list >> Thorax >>article
Thorax

Thorax

IF: 9
Download PDF

Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings.

Published:1 March 2004 DOI: 10.1136/thorax.2003.012658 PMID: 14985565
C M Chu, V C C Cheng, I F N Hung, M M L Wong, K H Chan, K S Chan, R Y T Kao, L L M Poon, C L P Wong, Y Guan, J S M Peiris, K Y Yuen

Abstract

Background: The clinical response of patients with severe acute respiratory syndrome (SARS) to a combination of lopinavir/ritonavir and ribavirin was examined after establishing the in vitro antiviral susceptibility of the SARS associated coronavirus to a panel of antiviral agents.

Methods: The in vitro susceptibility of the prototype of SARS associated coronavirus to a panel of nucleoside analogues and protease inhibitors currently licensed for clinical use was studied. Forty one patients with SARS followed for 3 weeks were treated with a combination of lopinavir/ritonavir and ribavirin. The clinical progress and virological outcomes were monitored and compared with 111 patients treated with ribavirin only who served as historical controls.

Results: In vitro antiviral activity against SARS associated coronavirus was demonstrated for lopinavir and ribavirin at concentrations of 4 micro g/ml and 50 micro g/ml, respectively, only at 48 hours. The adverse clinical outcome (ARDS or death) was significantly lower in the treatment group than in the historical controls (2.4% v 28.8%, p<0.001) at day 21 after the onset of symptoms. The adverse outcome remained significantly lower in the treatment group than in the controls-both those diagnosed early (p<0.001) and those diagnosed later in the course of the epidemic (p = 0.002)-but there was no significant difference in adverse outcome rates between the two time periods (p = 0.548). No time related difference in outcome was observed in the control groups. A reduction in steroid usage and nosocomial infections was seen in patients initially treated with lopinavir/ritonavir, and these patients had a decreasing viral load and rising peripheral lymphocyte count. Multivariate analysis showed that age, hepatitis B carrier status, and lack of treatment with this antiviral combination were independent predictors of an adverse outcome. Lopinavir/ritonavir treatment was associated with a better outcome even when adjusted for baseline lactate dehydrogenase level.

Conclusions: The apparent favourable clinical response with lopinavir/ritonavir and ribavirin supports further randomised placebo controlled trials in patients with SARS.

Substances (3)

Related products
Procduct Name CAS Molecular Formula Supplier Price
Ribavirin 36791-04-5 C8H12N4O5 744 suppliers $5.00-$3050.00
Ritonavir 155213-67-5 C37H48N6O5S2 695 suppliers $5.00-$1624.00
Lopinavir 192725-17-0 C37H48N4O5 410 suppliers $12.00-$2590.00

Similar articles

IF:13

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Drugs Risto S Cvetkovic, Karen L Goa,etc Published: 1 January 2003
IF:2.8

Role of isavuconazole in the treatment of invasive fungal infections.

Therapeutics and Clinical Risk Management Dustin T Wilson, V Paul Dimondi,etc Published: 3 August 2016
天长市| 乌审旗| 江永县| 中牟县| 板桥市| 贵定县| 通山县| 依兰县| 琼海市| 保定市| 同江市| 贵港市| 天气| 北宁市| 海丰县| 云南省| 历史| 大连市| 浦东新区| 府谷县| 昌黎县| 抚顺市| 竹北市| 大荔县| 合川市| 永城市| 左权县| 永靖县| 洛阳市| 松原市| 德格县| 修水县| 彩票| 防城港市| 辰溪县| 衡水市| 崇阳县| 积石山| 抚州市| 贵阳市| 固阳县|